Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer

International Journal of Cancer

Volumn 125, Issue 7, 2009, Pages 1728-1734

  Kluge, Amy ^a   Dabir, Snehal ^a   Kern, Jeffrey ^b   Nethery, David ^b   Halmos, Balazs ^a   Ma, Patrick ^a   Dowlati, Afshin ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Lung cancer; PIAS3; STAT3

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; INTERLEUKIN 6; PROTEIN INHIBITOR OF ACTIVATED SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION PROTEIN 3; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SEQUENCE; DRUG DNA BINDING; DRUG POTENTIATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; LUNG NEOPLASMS; MOLECULAR CHAPERONES; PLASMIDS; PROTEIN INHIBITORS OF ACTIVATED STAT; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TRANSFECTION; UP-REGULATION;

EID: 68549117088     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24553     Document Type: Article

References (25)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
3. Levy DE, Darnell JE, Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002;3:651-62.
4. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006;66:3162-8.
5. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle 2005;4:1131-3.
6. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-7.
7. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003;22:4150-65.
8. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-54.
9. Dowlati A, Nethery D, Kern JA. Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther 2004;4:459-63.
10. Dowlati A, Kluge A, Nethery D, Halmos B, Kern JA. SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/ human epidermal growth factor receptor 2. Anticancer Drugs 2008;19:9-16.
11. Boehm AL, Sen M, Seethala R, Gooding WE, Freilino M, Wong SM, Wang S, Johnson DE, Grandis JR. Combined targeting of eGFR STAT3, and Bcl-XL enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol 2008;73:1632-42.
12. Sharrocks AD. PIAS proteins and transcriptional regulation-more than just SUMO E3 ligases? Genes Dev 2006;20:754-8.
13. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997;278:1803-5.
14. Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene 2000;19:2638-44.
15. Wang L, Banerjee S. Differential PIAS3 expression in human malignancy. Oncol Rep 2004;11:1319-24.
16. Gross M, Liu B, Tan J, French FS, Carey M, Shuai K. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene 2001;20:3880-7.
17. Wang LH, Yang XY, Mihalic K, Xiao W, Li D, Farrar WL. Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3. J Biol Chem 2001;276:31839-44.
18. Junicho A, Matsuda T, Yamamoto T, Kishi H, Korkmaz K, Saatcioglu F, Fuse H, Muraguchi A. Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun 2000;278:9-13.
19. Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, Shuai K. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA 1998;95:10626-31.
20. Yang L, Williams DE, Mui A, Ong C, Krystal G, van Soest R, Andersen RJ. Synthesis of pelorol and analogues: activators of inositol 5-phosphatase SHIP. Org Lett 2005;7:1073-76.
21. Kluge A, Nethery D, Kern JA, Eisenberg R, Halmos B, Ma P, Dowlati A. Protein inhibitor of activated STAT3 is expressed in human lung cancer and is under epigenetic control. Proc Am Assoc Cancer Res 2008, abstract 3455.
22. Sonnenblick A, Levy C, Razin E. Interplay between MITF PIAS3, and STAT3 in mast cells and melanocytes. Mol Cell Biol 2004;24:10584-92.
23. Nojiri S, Joh T, Miura Y, Sakata N, Nomura T, Nakao H, Sobue S, Ohara H, Asai K, Ito M. ATBF1 enhances the suppression of STAT3 signaling by interaction with PIAS3. Biochem Biophys Res Commun 2004;314:97-103.
24. Long J, Wang G, Matsuura I, He D, Liu F. Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3). Proc Natl Acad Sci USA 2004;101:99-104.
25. Junicho A, Matsuda T, Yamamoto T, Kishi H, Korkmaz K, Saatcioglu F, Fuse H, Muraguchi A. Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun 2000;278:9-13.